UnknownPhase 2

Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

Russia17 participantsStarted 2019-04-13

Plain-language summary

Treatment Study to assess of safety and efficiency of conditioning with Plerixafor and G-CSF as additional agents for prevention of graft failure after transplantation in patients with chronic granulomatous disease

Who can participate

Age range1 Month – 24 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients aged ≥ 1 months and \< 25 years Patients diagnosed with CGD eligible for an allogeneic transplantation Signed written informed consent Exclusion Criteria: Lack of informed consent.

What they're measuring

Event free survival

Timeframe: 1 year

Trial details

NCT IDNCT03547830

SponsorFederal Research Institute of Pediatric Hematology, Oncology and Immunology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01-01

Contact for this trial

Dmitry Balashov, MD

+79265791817 bala8@yandex.ru

View on ClinicalTrials.gov More Chronic Granulomatous Disease trials